Executive SummaryInvestigations currently going on in the New York State Attorney General's office are looking into charges that analysts at investment banks often give misleading advice on companies in order to support the banks' M&A activities. Such conflicts of interest aren't hard to understand. But for medical device companies, the implicit notion--that investment banks are friendly places that bend over backward to say nice things--runs counter to their experience.
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.